Doctors Note Logo

Published on: 6/17/2026

Macular Degeneration: What Doctors Use to Slow Vision Loss in Wet vs. Dry AMD

Age-related macular degeneration (AMD) treatment depends on the type. Dry AMD is managed with AREDS2 supplements, a diet rich in leafy greens and omega-3 fatty acids, blood pressure and weight control, and routine eye exams to track progression. Wet AMD requires anti-VEGF injections such as Lucentis, Eylea, or Avastin, and may also involve photodynamic or laser therapy to seal leaking blood vessels.

Below, you'll find key details on dosing schedules, follow-up care, treatment risks, and emerging therapies that could shape your next steps.

Because AMD symptoms can overlap with other vision conditions—and early intervention dramatically improves outcomes—it's worth taking a few minutes to clarify what you're experiencing before your next appointment. A free, instant, online symptom check can help you understand your symptoms and guide your next steps with confidence.

Reviewed for medical accuracy: 06/17/2026

answer background

Explanation

Macular Degeneration Treatment: Slowing Vision Loss in Wet vs. Dry AMD

Age-related macular degeneration (AMD) is a leading cause of vision loss in adults over 50. It damages the macula, the part of the eye responsible for sharp, central vision. There are two main forms:

  • Dry AMD (non-neovascular): Gradual breakdown of light-sensing cells in the macula.
  • Wet AMD (neovascular): Abnormal blood vessels grow under the retina, leaking fluid or blood.

While neither form can be cured, doctors use medical treatments and lifestyle changes to slow vision loss, preserve quality of life, and monitor for progression.


General Strategies for Slowing Vision Loss

Regardless of whether AMD is wet or dry, some steps can help protect your eyes and overall health:

  • Quit smoking
    Tobacco accelerates macular damage and increases AMD risk.

  • Healthy diet
    Focus on green leafy vegetables, colorful fruits, fish rich in omega-3s, and nuts.

  • Maintain healthy weight and blood pressure
    Obesity and hypertension can worsen AMD progression.

  • Regular eye exams
    Early detection allows timely treatment.

  • Home monitoring
    Use an Amsler grid daily to spot new distortions or dark areas in your central vision.

  • Protect your eyes from UV light
    Wear sunglasses with UV protection when outdoors.


Dry AMD Treatment

Dry AMD accounts for about 85–90% of all cases. Damage is slow but irreversible once cells die. Treatment focuses on nutritional support and close monitoring.

AREDS and AREDS2 Supplements

The National Eye Institute studied two formulations:

  • AREDS (Age-Related Eye Disease Study)
  • AREDS2 (updated with lutein/zeaxanthin, lower zinc)

Key components:

  • Vitamin C (500 mg)
  • Vitamin E (400 IU)
  • Zinc (80 mg as zinc oxide)
  • Copper (2 mg as cupric oxide)
  • Lutein (10 mg) & Zeaxanthin (2 mg) in AREDS2
  • Omega-3 fatty acids (in some trials)

Who benefits?

  • Intermediate AMD in one or both eyes
  • Advanced AMD in one eye only

Lifestyle and Vision Aids

  • Dietary focus on foods rich in macular pigments (e.g., spinach, kale, eggs).
  • Low-vision aids, such as magnifiers, adaptive lighting, and screen-reader software, can help maintain independence.

Monitoring and Follow-Up

  • Regular eye exams (every 6–12 months).
  • Home Amsler grid checks to detect a possible switch to wet AMD.

Wet AMD Treatment

Wet AMD is more aggressive but highly responsive to treatments that block abnormal blood vessel growth. Early intervention is key to preserving vision.

Anti-VEGF Injections

VEGF (vascular endothelial growth factor) fuels abnormal vessel growth. Injecting anti-VEGF medications into the eye reduces leakage and stabilizes vision.

Common agents:

  • Ranibizumab (Lucentis)
  • Aflibercept (Eylea)
  • Bevacizumab (used off-label; Avastin)
  • Brolucizumab (Beovu)

Treatment protocols:

  • Initial monthly injections for 3–6 months.
  • Then "treat-and-extend" or "as-needed" schedules based on eye exams and optical coherence tomography (OCT) scans.

Benefits and considerations:

  • Can improve or stabilize vision in 70–90% of patients.
  • Risks include infection, bleeding, and elevated eye pressure (rare).
  • Requires commitment to frequent eye-clinic visits.

Photodynamic Therapy (PDT)

  • Verteporfin (Visudyne) is injected into a vein, then activated by a cold laser aimed at abnormal vessels.
  • Less common now but may help certain lesion types.

Laser Photocoagulation

  • High-energy laser burns and seals off leaky vessels.
  • Used only in rare cases where vessels are far from the central macula, as it can create blind spots.

Emerging and Investigational Therapies

Researchers are exploring new ways to slow or reverse AMD:

  • Gene therapy to target VEGF production.
  • Stem cell transplants to replace damaged retinal cells.
  • Complement inhibitors to reduce inflammation in dry AMD.
  • Sustained-release drug implants to reduce injection frequency.

While promising, these treatments are still under study. Discuss clinical trial options with your ophthalmologist if you meet eligibility criteria.


Why Early Detection Matters

  • Dry AMD can convert to wet AMD at any time. Early wet AMD treatment preserves vision.
  • Home monitoring and regular exams are vital.

If you're experiencing vision changes or distortions, you can use a free AI-powered symptom checker to assess your risk for Age-Related Macular Degeneration and determine whether you need to schedule an eye exam right away.


When to Speak to a Doctor

  • Sudden vision changes (distortion, blind spots, dark patches) require prompt assessment.
  • Serious side effects after injections, such as pain, redness, or severe headache, need immediate attention.
  • Any new health concerns or life-threatening symptoms should be discussed with a medical professional right away.

Always talk with your doctor or retinal specialist about the best combination of treatments for your situation. Early and consistent care is the most effective way to slow vision loss from both wet and dry AMD.

(References)

  • * Schmidt-Erfurth U, Waldstein SM, Ruetsch C, Tode J, Wagner L. Age-Related Macular Degeneration: An Update on Current Treatments. Cells. 2023 Jul 26;12(15):2001. doi: 10.3390/cells12152001. PMID: 37571871; PMCID: PMC10376179.

  • * Rosenfeld PJ, Kim R, Lam BL, Yuan G, Lowy J, Zheng D. Targeting Geographic Atrophy in Age-Related Macular Degeneration. Cells. 2022 Nov 17;11(22):3655. doi: 10.3390/cells11223655. PMID: 36459346; PMCID: PMC9676579.

  • * Brown DM, Singh RP, Kim R, Lam BL, Yuan G, Lowy J, Zheng D. Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration. Cells. 2022 Nov 16;11(22):3649. doi: 10.3390/cells11223649. PMID: 36459340; PMCID: PMC9676239.

  • * Khetpal V, Kim R, Lam BL, Yuan G, Lowy J, Zheng D. Advances in the Management of Age-Related Macular Degeneration. Cells. 2022 Nov 16;11(22):3645. doi: 10.3390/cells11223645. PMID: 36459336; PMCID: PMC9676226.

  • * Jager R, Singh R. Emerging Pharmacotherapies for Geographic Atrophy. J Clin Med. 2023 Nov 21;12(22):7309. doi: 10.3390/jcm12227309. PMID: 38002621; PMCID: PMC10670566.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.